Skip to main content
. 2012 Dec;24(4):263–274. doi: 10.3978/j.issn.1000-9604.2012.10.04

Table 2. Clinicopathological features in relation to Gli1 nuclear immunoreactivity.

Case No. Gli1 nuclear immunoreactivity
 P
Low High
Age (year)
    ≤35 12 6 6 <0.001
    36–59 180 37 143
    ≥60 92 5 87
T-classification
    T1 148 23 125 0.094
    T2 105 15 90
    T3 29 9 20
    T4 2 1 1
N-classification
    N0 147 23 124 0.080
    N1 107 15 92
    N2 25 8 17
    N3 5 2 3
Clinical stage
    I 129 26 103 0.362
    II 113 15 98
    III 42 7 35
ER presence
    Negative 115 21 94 0.616
    Positive 169 27 142
PR presence
    Negative 138 25 113 0.597
    Positive 146 23 123
HER-2 presence
    Negative 88 18 70 0.019
    Positive 196 30 166

Low, IRS=0-6; High, IRS=7-12; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2